Xintela AB Interim Report January – March 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 15,843 (loss: 16,383).Loss per share* was SEK 0.05 (loss: 0.18). First quarter 2023 for the parent companyIncome amounted to TSEK 0 (0).Loss before […]
Communiqué from the Annual General Meeting of Xintela AB (publ)
Today, Friday 12 May 2023, the Annual General Meeting was held in Xintela AB (publ). The following main decisions were made. The decisions were taken unanimously. Profit allocation and decision on discharge from liabilityThe meeting decided, in accordance with the board’s proposal, that no dividend is to be paid for the financial year 2022 and […]
Xintela AB publishes Annual Report 2022
Xintela AB (publ) announces that the Swedish version of the company’s Annual Report for 2022 is published on the company’s website, www.xintela.se. The English version will be published shortly. Link to the annual report:https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical […]
Xintela Year-end report 2022
Summary of the year-end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2022 for the group Fourth quarter 2022 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 23,384 (loss: 18,013).Loss per share* was SEK 0.09 (loss: 0.20). Twelve months 2022 for the groupIncome […]
Xintela and NorthX Biologics sign collaboration framework agreement
Xintela and NorthX Biologics announce they have signed a collaboration framework agreement to facilitate projects of common interest utilizing their complementary resources and competences in developing and manufacturing Advanced Therapy Medicinal Products (ATMPs). Projects to be initiated under the collaboration framework include product and process development, quality management and expansion capacity for manufacturing ATMPs, among […]
Xintela AB Interim Report January – September 2022
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2022 for the group» Income amounted to TSEK 0 (0)» Loss before and after tax totalled TSEK 14,456 (loss: 15,892)» Loss per share* was SEK 0.11 (loss: 0.20) First nine months 2022 for the group» Income […]
Xintela proposes Thomas Eldered as new Board member
Major shareholder in Xintela AB (publ) proposes that the company’s shareholders elect Thomas Eldered as a new member of the Board at the Extra General Meeting on November 28, 2022. The board of directors announces the proposal regarding election of new Board member at the Extra General Meeting on November 28, 2022. The company’s major […]
Targinta appoints Peter Ekolind as acting CEO
Targinta’s board has appointed Peter Ekolind as acting CEO, starting from October 1, 2022, as a part-time assignment, due to Per Norlén’s resignation as CEO. Peter Ekolind has more than 30 years of experience from operational and strategic positions at management level in the pharmaceutical and medical technology industry, from multinational companies to small development […]
Xintela AB Interim Report January – June 2022
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 2022 for the group» Income amounted to TSEK 0 (0).» Loss before tax totalled TSEK 18,942 (loss: 15,020).» Loss per share was SEK 0.21 (loss: 0.17). First half year 2022 for the group» Income amounted to […]
Notice from annual general meeting in Xintela AB (publ)
Today, Friday 6 May 2022, the annual general meeting in Xintela AB (publ) was held. The following main resolutions were passed. Allocation of results and discharge from liabilityThe meeting resolved, in accordance with the board’s proposal, that no dividend shall be paid for the financial year 2021 and that the company’s result shall be carried […]
